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Introduction:  The  evidence  for  beta-blocker  use  in  patients  after  acute  coronary  syndrome
(ACS), particularly  in  those  with  left  ventricular  (LV)  dysfunction,  dates  from  the  late  1990s.
We aimed  to  assess  the  role  of  beta-blockers  in  a  contemporary  population  of  patients  with
ACS.
Methods: Propensity-score  matching  (1:2)  was  performed  for  the  use  of  beta-blockers  in  a
population  of  consecutive  patients  admitted  to  our  department  with  ACS.  After  matching,
1520 patients  were  analyzed.  Cox  regression  analysis  was  used  to  assess  the  impact  of  beta-
blocker use  on  the  primary  outcome  (one-year  all-cause  mortality).
Results:  Patients  who  did  not  receive  beta-blockers  were  less  aggressively  treated  with  other
pharmacological  and  invasive  interventions  and  had  higher  one-year  mortality  (20.3%  vs.  7.5%).
Beta-blocker  use  was  an  independent  predictor  of  mortality,  with  a  signiﬁcant  relative  risk
reduction of  56%.  The  other  independent  predictors  were  age,  diabetes,  LV  dysfunction,  heart
rate, systolic  blood  pressure  and  creatinine  on  admission.  The  impact  of  beta-blockers  was  sig-
niﬁcant for  all  classes  of  LV  function,  including  patients  with  normal  or  mildly  reduced  ejection
fraction.
Conclusions:  In  a  contemporary  ACS  population,  we  conﬁrmed  the  beneﬁts  of  beta-blocker  use
after ACS,  including  in  patients  with  normal  or  mildly  to  moderately  impaired  LV  function.
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Qual  o  papel  dos  bloqueadores-beta  numa  coorte  de  tratamento  contemporânea
de  doentes  com  síndrome  coronária  aguda?  Análise  de  emparelhamento  de  score
de  propensão
Resumo
Introduc¸ão:  A  evidência  para  a  utilizac¸ão  dos  bloqueadores-beta  em  doentes  após  síndrome
coronária  aguda  (SCA),  particularmente  em  doentes  com  disfunc¸ão  ventricular  esquerda  (VE)  é
do ﬁnal  dos  anos  90.  Foi  nosso  objetivo  analisar  o  papel  dos  bloqueadores-beta  numa  populac¸ão
contemporânea  de  doentes  com  SCA.
Métodos:  Foi  realizado  emparelhamento  de  score  de  propensão  (1:2)  para  a  utilizac¸ão  de
bloqueadores-beta  numa  populac¸ão  consecutiva  de  doentes  admitidos  no  nosso  servic¸o  por  SCA.
Após emparelhamento,  foram  analisados  1520  doentes.  Foi  utilizada  a  análise  de  regressão  de
Cox para  avaliar  o  impacto  da  utilizac¸ão  dos  bloqueadores-beta  na  mortalidade  de  todas  as
causas a  um  ano  de  seguimento.
Resultados:  Os  doentes  que  não  receberam  bloqueadores-beta  foram  tratados  de  forma  menos
agressiva com  outras  intervenc¸ões  farmacológicas  e  invasivas  e  tiveram  maior  mortalidade  a
um ano  (20,3%  versus  7,5%).  A  utilizac¸ão  de  bloqueadores-beta  foi  preditor  independente  de
mortalidade  com  reduc¸ão  signiﬁcativa  do  risco  relativo  de  56%.  Os  restantes  preditores  inde-
pendentes foram  a  idade,  diabetes,  disfunc¸ão  VE,  frequência  cardíaca,  pressão  arterial  sistólica
e creatinina  na  admissão.  O  impacto  dos  bloqueadores-beta  foi  signiﬁcativo  em  todas  as  classes
de func¸ão  VE,  incluindo  doentes  com  frac¸ão de  ejec¸ão  normal  ou  ligeiramente  reduzida.
Conclusões:  Numa  populac¸ão  contemporânea  de  doentes  com  SCA,  conﬁrmámos  os  benefícios
da terapêutica  bloqueadora-beta  após  SCA,  incluindo  em  doentes  com  func¸ão  VE  normal  ou
com compromisso  ligeiro  a  moderado.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
List  of  abbreviations
ACEI  angiotensin-converting  enzyme  inhibitor
ACS  acute  coronary  syndrome
ARB  angiotensin  receptor  blocker
AV  atrioventricular
CABG  coronary  artery  bypass  grafting
CI  conﬁdence  interval
HR  hazard  ratio
LV  left  ventricular
LVEF  left  ventricular  ejection  fraction
NSTE-ACS  non-ST-elevation  acute  coronary  syndrome
PCI  percutaneous  coronary  intervention
STEMI  ST-elevation  myocardial  infarction
TIA  transient  ischemic  attack
Introduction
The  role  of  beta-blockers  is  clearly  established  for  secondary
prevention  in  all  current  guidelines  for  the  management
of  patients  with  acute  coronary  syndromes  (ACS),  particu-
larly  in  the  presence  of  left  ventricular  (LV)  dysfunction.1,2
Beta-blockers  improve  outcome  in  coronary  artery  dis-
ease  by  reducing  oxygen  demand  and  hence  ischemia,
attenuating  ventricular  remodeling,  and  preventing  lethal
arrhythmias  and  sudden  death.  However,  the  majority
of  studies  that  support  these  effects  were  performed
between  the  1970s  and  the  1990s,  before  major  advances
in  therapy  such  as  the  introduction  of  reperfusion  ther-
apy  and  modern  pharmacotherapy.3--10 Beta-blockers  have
not  been  investigated  in  contemporary  trials,  although  it
is  not  unreasonable  to  extrapolate  their  beneﬁts  to  this
setting.
Each  successive  intervention  that  reduces  risk  reduces
the  absolute  beneﬁt  of  further  interventions.  Dramatic
decreases  in  mortality  were  observed  in  the  early  21st
century  in  several  ACS  registries.11--17 As  the  baseline  risk
of  a population  decreases  due  to  a  new  intervention,  the
incremental  beneﬁt  of  previous  interventions  needs  to  be
re-evaluated.  Currently,  most  ACS  patients  are  discharged
without  signiﬁcant  residual  ischemia,  and  the  risk  of  lethal
arrhythmias  is  extremely  low  because  remodeling  and  even
quite  large  reductions  in  LV  ejection  fraction  (LVEF)  with
heart  failure  are  not  a  signiﬁcant  problem  with  contempo-
rary  treatment.  A  more  recent  study  in  stable  CAD  patients
challenged  the  use  of  beta-blockers,  further  reinforcing  the
need  for  reassessment  of  their  beneﬁt  in  a  contemporary
cohort  of  patients  with  ACS.18 Also,  current  guidelines  do
not  provide  a  deﬁnite  recommendation  for  the  use  of  beta-
blockers  in  patients  with  ACS  and  normal  or  mildly  reduced
LVEF  (≥40%).1,2
It  was  our  objective  to  assess  the  role  of  beta-blockers  in
a  contemporary  population  of  patients  with  ACS.
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Methods
All  consecutive  adult  patients  (aged  ≥18  years)  admitted  to
our  intensive  care  unit  with  ACS  were  prospectively  included
in  our  center’s  ACS  registry  between  January  2005  and
November  2015  and  were  included  in  the  present  study.  Cri-
teria  for  inclusion  were  a  history  of  chest  pain  at  rest  or
other  symptoms  suggestive  of  ACS  (the  most  recent  episode
within  48  hours  of  admission)  with  or  without  new  or  pre-
sumed  new  signiﬁcant  ST-segment  or  T-wave  changes,  new
left  bundle  branch  block  and  elevated  biomarkers  of  myocar-
dial  damage  with  a  rise  and/or  fall  in  levels.  Myocardial
infarction  (MI)  was  deﬁned  according  to  the  universal  deﬁ-
nition  of  type  1  MI.19 A  diagnosis  of  ST-elevation  MI  (STEMI)
was  made  in  the  presence  of  persistent  (>30  min)  ST-segment
elevation.  All  other  cases  were  considered  non-ST  elevation
ACS  (NSTE-ACS).
Data  were  collected  in  a  dedicated  electronic
database,  and  included  demographic,  clinical  and  patient-
management  related  characteristics,  as  well  as  clinical
outcome.  Hypertension,  diabetes  and  hyperlipidemia  were
deﬁned  as  either  previously  known  or  on  speciﬁc  therapy.
If  patients  had  smoked  during  the  previous  six  months
they  were  classiﬁed  as  smokers  and  were  self-reported.
Decisions  on  patient  management  strategy,  including
referral  for  coronary  angiography  and  mode  of  myocardial
revascularization,  if  any,  were  at  the  discretion  of  the
attending  physician.  LVEF  was  obtained  before  discharge  by
echocardiography.
Follow-up  was  obtained  for  every  patient  who  survived  to
discharge  by  reviewing  medical  records  and/or  by  telephone
interview  with  the  patient  or  family  members.  The  primary
endpoint  was  all-cause  mortality  at  one-year  follow-up.
In-hospital  secondary  endpoints  were  cardiac  arrest,  com-
plete  atrioventricular  (AV)  block,  mechanical  complications,
stroke/transient  ischemic  attack  (TIA),  LV  function,  major
bleeding  (according  to  the  Global  Use  of  Strategies  to  Open
Occluded  Coronary  Arteries  [GUSTO]  criteria),  and  all-cause
mortality  during  the  index  hospitalization  and  at  30-day
follow-up.20
All  procedures  contributing  to  this  work  comply  with
the  ethical  standards  of  the  1975  Helsinki  Declaration.  This
research  does  not  involve  human  or  animal  experimentation.
Statistical  analysis
Continuous  variables  are  reported  as  means  and  standard
deviation  and  were  compared  with  the  Student’s  t  test.  Nor-
mality  tests  were  performed  with  the  Kolmogorov-Smirnov
test  and  homogeneity  of  variance  was  tested  with  Levene’s
test.  Continuous  variables  without  normal  distribution  are
reported  as  medians  and  interquartile  range  and  were  com-
pared  with  the  Mann-Whitney  test.  Categorical  variables  are
reported  as  percentages  and  differences  between  groups
were  tested  with  the  chi-square  test  or  Fischer’s  exact  test,
as  appropriate.
Propensity-score  matching  was  performed  to  adjust  for
the  non-randomized  assignment  of  patients  to  treatment
and  for  the  potential  bias  due  to  differences  between  the
study  groups.  Propensity  scoring  helps  deal  with  bias  arising
from  confounding  by  indication,  enabling  a  more  accurate
comparison  of  outcomes  between  participants  with  similar
propensity  scores  based  on  the  set  of  available  information
about  that  individual.  A  propensity  score  was  calculated  for
each  participant  by  logistic  regression  as  the  likelihood  of
being  assigned  to  treatment  with  a  beta-blocker.  The  model
included  all  variables  that  in  the  logistic  analysis  had  a
p-value  <0.05.  A  1:2  matched  analysis  was  then  performed
on  the  basis  of  each  patient’s  estimated  propensity  score.
Baseline  and  in-hospital  characteristics  were  then  com-
pared.
Estimates  of  event-free  survival  at  one-year  follow-up
were  calculated  by  the  Kaplan-Meier  method  and  sur-
vival  curves  were  compared  with  the  log-rank  test.  A  Cox
proportional-hazards  regression  model  was  used  with  the
p  level  for  entry  into  and  removal  from  the  model  set  at
0.05  and  0.10,  respectively  (forward  stepwise  method  with
likelihood  ratio  statistics),  to  select  variables  that  were
independent  predictors  of  all-cause  mortality.  Estimates  of
the  association  between  predictors  and  endpoints  are  pre-
sented  as  hazard  ratio  (HR)  and  95%  conﬁdence  interval  (CI).
For  all-cause  mortality,  subgroup  analysis  was  performed
according  to  gender,  age  (<70  years  and  ≥70  years),  pres-
ence  or  absence  of  diabetes,  STEMI  vs.  NSTE-ACS,  and  LVEF
(<35%,  35-50%  and  ≥50%).  This  categorization  of  LV  function
was  used  since  it  was  the  one  available  in  our  database;  spe-
ciﬁc  LVEF  values  were  not  available  for  all  patients.  Analysis
of  the  interaction  between  beta-blocker  therapy  and  each
subgroup  was  performed  using  Cox  regression  models.
IBM  SPSS  statistical  software  (version  19.0.0.2)  was  used
for  all  statistical  analyses.  All  statistical  tests  were  two-
sided  with  a  value  of  0.05  for  statistical  signiﬁcance.
Results
Of  a  total  of  3536  patients  included  in  our  registry  during  the
study  period,  83.4%  received  beta-blocker  treatment.  After
propensity-score  matching,  1520  patients  were  selected  for
analysis.  The  population’s  characteristics  were  well  bal-
anced  between  groups  (Table  1);  the  absolute  standardized
difference  of  less  than  10%  for  all  variables  indicates  ade-
quate  matching.  Patients’  mean  age  was  66±13  years,  most
were  male  (68%),  and  the  most  frequent  diagnosis  was
STEMI  (61.6%  of  patients).  In  patients  who  died  very  early
in  the  course  of  admission,  before  a  complete  echocardio-
gram  was  performed  (1.3%),  an  admission  echocardiogram
or  information  from  ventriculography  was  used  to  assess
LV  function.  Follow-up  information  was  obtained  in  99.8%
of  patients.  In-hospital,  30-day  and  one-year  mortality
were  7.5%,  8.7%  and  11.8%,  respectively.  In  this  matched
cohort,  patients  who  did  not  receive  beta-blockers  were
also  less  likely  to  receive  antiplatelet  therapy,  angiotensin-
converting  enzyme  inhibitors/angiotensin  receptor  blockers
(ACEIs/ARBs),  statins  and  revascularization  (Table  2).  Also,
all-cause  mortality,  mechanical  complications  and  cardiac
arrest  were  signiﬁcantly  more  frequent  in  patients  not
treated  with  beta-blockers.  The  rate  of  complete  AV  block
and  stroke/TIA  was  similar  in  both  groups.
In  univariate  Cox  regression  analysis,  the  use  of  beta-
blockers  was  associated  with  better  outcome  in  the  overall
population  (HR  0.34,  95%  CI  0.25-0.45,  p<0.001).  In  the
multiple  Cox  proportional-hazards  regression  model,  the
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Table  1  Baseline  clinical  characteristics  after  propensity-score  matching.
No  beta-blocker  therapy  (n=507)  Beta-blocker  therapy  (n=1013)  p
Age,  years 66  (13) 66  (13) 0.914
Male gender,  %  68.2  68.7  0.901
Risk factors,  %
Hypertension  61.9  62.3  0.937
Hyperlipidemia  47.9  46.5  0.636
Diabetes 25.0  27.8  0.274
Smoking 33.9  33.5  0.903
Previous history,  %
MI 13.2  15.2  0.337
PCI 8.9 9.0  1.000
CABG 3.4  4.9  0.199
Previous revascularization  11.8  12.4  0.798
Initial presentation
Heart  rate,  bpm  75  (21)  75  (18)  0.783
SBP, mmHg 131  (26)  130  (27)  0.651
Killip class  >I,  % 15.8 14.6  0.599
Killip class  IV,  % 3.4  2.1  0.132
STEMI, % 58.2 63.4  0.057
Creatinine, mg/dl 1.1  (0.8)  1.0  (0.6)  0.05
bpm: beats per minute; CABG: coronary artery bypass grafting; MI: myocardial infarction; PCI: percutaneous coronary intervention; SBP:
systolic blood pressure; STEMI: ST-elevation myocardial infarction.
Table  2  Treatment  and  outcome.
No  beta-blocker  therapy  (n=507)  Beta-blocker  therapy  (n=1013)  p
Aspirin,  %  88.2  98.8  <0.001
DAPT, %  81.1  94.6  <0.001
ACEI/ARB, %  66.7  91.0  <0.001
Statin, %  78.3  95.2  <0.001
PCI, %  68.2  80.6  <0.001
CABG, %  1.2  3.1  0.038
Revascularizationa,  %  69.4  83.6  <0.001
Cardiac arrest,  %  11.6  7.5  0.010
Complete AV  block,  %  2.8  2.7  1.000
LVEF, %  0.970
>50 65.7  66.1
35-50 23.7  23.1
<35 10.7  10.8
Mechanical  complications,  %  13.2  5.6  <0.001
Stroke/TIA, %  1.6  0.7  0.099
Major bleeding,  %  4.7  3.0  0.107
In-hospital mortality,  %  15.0  3.8  <0.001
30-day mortality,  %  16.2  4.9  <0.001
One-year mortality,  %  20.3  7.5  <0.001
a Revascularization includes PCI and/or CABG.
ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; AV: atrioventricular; CABG: coronary artery bypass
grafting; DAPT: double antiplatelet therapy; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; TIA:
transient ischemic attack.
use  of  beta-blockers  remained  an  independent  predictor
of  better  outcome,  together  with  the  use  of  ACEIs/ARBs
(Table  3  and  Figure  1).  Age,  heart  rate,  systolic  blood
pressure,  diabetes,  LVEF,  ACEI/ARB  use,  renal  function
and  mechanical  complications  were  the  other  independent
predictors  of  all-cause  mortality  in patients  with  ACS.
In  the  subgroup  analysis  (Figure  2),  all  subgroups  had
a  better  outcome  with  the  use  of  beta-blockers,  including
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Table  3  Univariate  and  multivariate  Cox  regression  analysis.
HR  (95%  CI)  p  HR  (95%  CI)  p
Age  (per  10-year  increase)  1.82  (1.59-2.08)  <0.001  2.03  (1.72-2.39)  <0.001
Male gender  0.59  (0.44-0.79)  <0.001
Diabetes 2.07  (1.54-2.79)  <0.001  1.99  (1.44-2.76)  <0.001
STEMI 1.31  (0.96-1.79)  0.088  -  -
Heart rate  (per  10-bpm  increase)  1.33  (1.26-1.42)  <0.001  1.17  (1.09-1.25)  <0.001
SBP (per  10-mmHg  increase)  0.87  (0.82-0.92)  <0.001  0.92  (0.86-0.98  0.017
Killip class  >1  3.82  (2.82-5.18)  <0.001  -  -
LVEF (decrease)  2.76  (2.31-3.29)  <0.001  1.84  (1.49-2.28)  <0.001
Creatinine 1.34  (1.24-1.45) <0.001 1.27  (1.13-1.42) <0.001
DAPT 0.51  (0.34-0.75) 0.001 -  -
ACEI/ARB 0.32  (0.24-0.44) <0.001 0.52  (0.35-0.76) 0.001
Beta-blocker  0.34  (0.25-0.45)  <0.001  0.44  (0.31-0.62)  <0.001
Statin 0.38  (0.27-0.55)  <0.001  -  -
Revascularization  0.49  (0.37-0.67)  <0.001  -  -
Mechanical  complication  12.32  (9.12-16.64)  <0.001  4.83  (3.30-7.08)  <0.001
ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; bpm: beats per minute; CI: conﬁdence interval; DAPT:




























Figure  1  Kaplan-Meier  survival  curve  comparing  patients  with  and  without  beta-blocker  therapy.
Figure  2  Subgroup  analysis.  CI:  conﬁdence  interval;  HR:  hazard  ratio;  LVEF:  left  ventricular  ejection  fraction;  NSTE-ACS:  non-ST-
elevation acute  coronary  syndrome;  STEMI:  ST-elevation  myocardial  infarction.
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patients  with  normal  or  mildly  to  moderately  reduced  LVEF,
in  both  univariate  and  multivariate  analysis.
Discussion
Several  trials  and  meta-analyses  have  demonstrated  that
beta-blockers  reduce  mortality  and  reinfarction  by  20-
25%  in  those  who  have  recovered  from  MI.3--10 Over
52  000  patients  were  randomized  in  clinical  trials  studying
beta-blockers  in  acute  MI,  covering  a  range  of  beta-
blockers,  and  largely  conducted  in  the  pre-reperfusion
era.  The  available  data  at  that  time  suggested  trends
toward  reductions  in  mortality,  reinfarction  and  cardiac
arrest,  if  used  in  patients  without  contraindications.  A
review  of  secondary  prevention  trials  of  beta-blocker
therapy  both  in  the  acute  phase  and  as  secondary  pre-
vention  showed  an  overall  beneﬁt,  with  a  relative  risk
reduction  of  19%  in  mortality,  particularly  for  secondary
prevention  (23%  relative  risk  reduction).10 The  Carvedilol
Post-Infarct  Survival  Control  in  Left  Ventricular  Dysfunc-
tion  (CAPRICORN)  trial  deﬁnitively  demonstrated  the  beneﬁt
of  beta-blockers  in  patients  with  LV  dysfunction  (LVEF
<40%)  after  MI  with  or  without  clinical  signs  of  heart
failure.9 However,  since  the  1980s,  aspirin,  P2Y12 inhibitors,
thrombolysis  followed  by  primary  angioplasty,  high-dose
statins,  enoxaparin,  mineralocorticoid  receptor  antagonists,
ACEIs,  implantable  cardioverter-deﬁbrillators,  and  early
revascularization  for  NSTE-ACS  have  all  been  introduced.
These  changes  in  management  were  followed  by  dramatic
decreases  in  mortality  in  the  early  21st  century  in  several
registries.11--17
COMMIT,  a  large  trial  performed  in  the  reperfusion
era,  showed  no  difference  in  the  rate  of  the  composite
endpoint  of  death,  reinfarction,  or  cardiac  arrest  in  the
metoprolol  group  compared  with  the  placebo  group,  but
signiﬁcant  reductions  occurred  in  reinfarction  and  episodes
of  ventricular  ﬁbrillation.21 A  meta-analysis  that  included
earlier  studies  and  low-risk  patients  from  the  COMMIT  trial
showed  reductions  of  13%  in  all-cause  mortality,  22%  in
reinfarction,  and  15%  in  ventricular  ﬁbrillation  or  cardiac
arrest.21 However,  in  order  to  achieve  these  beneﬁts
safely,  it  is  important  to  avoid  early  administration  of
beta-blockers  to  patients  with  relative  contraindications.
Another  paper  challenged  the  beneﬁcial  effect  of  beta-
blockers  after  ACS.18 In  an  observational  study  with
propensity-score  matching,  with  a  median  follow-up  of
44  months  in  stable  outpatients  with  and  without  coronary
artery  disease,  the  use  of  beta-blockers  was  not  associ-
ated  with  a  lower  risk  of  cardiovascular  events  (primary
outcome:  a  composite  of  cardiovascular  death,  nonfatal  MI
or  nonfatal  stroke;  secondary  outcome:  the  primary  out-
come  plus  hospitalization  for  atherothrombotic  events  or
revascularization;  tertiary  outcomes:  all-cause  mortality,
cardiovascular  mortality,  nonfatal  MI,  nonfatal  stroke,  and
hospitalization  separately),  including  in  the  cohort  with
prior  MI.  However,  in  those  with  recent  MI  (≤1  year),  beta-
blocker  use  was  associated  with  a  lower  incidence  of  the
secondary  outcome  (odds  ratio  0.77).
In  view  of  these  uncertainties  and  contradictions  and  the
limited  evidence,  the  purpose  of  our  study  was,  based  on
a  real-world  contemporary  population  of  patients  from  an
ACS  registry,  to  assess  whether  beta-blocker  therapy  is  still
beneﬁcial,  on  top  of  all  guideline-recommended  therapies.
We  observed  not  only  that  the  magnitude  of  beneﬁt  is  highly
signiﬁcant,  with  a  relative  risk  reduction  in  one-year  all-
cause  mortality  of  56%,  but  also  that  this  beneﬁt  is  the  same
for  STEMI  and  NSTE-ACS  patients,  and  most  importantly  is
independent  of  LV  function.
A  recent  study  based  on  a  UK  registry  showed  that  in
survivors  of  hospitalization  with  MI  who  did  not  have  heart
failure  or  LV  systolic  dysfunction,  the  use  of  beta-blockers
was  not  associated  with  a lower  risk  of  death  up  to  one
year.22 This  result  is  clearly  different  from  ours,  but  their
sample  has  different  characteristics.  Ours  had  a  predom-
inance  of  patients  with  STEMI,  and  Dondo  et  al.’s  study
only  included  patients  who  survived  to  discharge.  Their  main
strength  is  that  it  has  a  very  large  sample  of  patients  and  also
used  propensity-score  matching.  However,  the  cutoff  used
for  systolic  dysfunction  was  LVEF  <30%,  and  they  therefore
included  patients  with  normal  and  mildly  and  moderately
impaired  systolic  function  in  the  same  analysis.  For  this  rea-
son,  we  also  performed  a  substudy  of  patients  who  survived
to  discharge.  In  those  patients,  a tendency  for  some  beneﬁt
was  found  for  beta-blocker  use  in  patients  with  LVEF  35-50%
(HR  0.46,  95%  CI  0.20-1.06,  p=0.069)  and  with  LVEF  >50%
(HR  0.42,  95%  CI  0.18-0.96,  p=0.036).  Surprisingly,  no  ben-
eﬁt  was  found,  in  terms  of  all-cause  mortality  at  one-year
follow-up,  in  patients  with  LVEF  <35%  (HR  0.25,  95%  CI  0.05-
1.26,  p=0.09)  (p=0.391  for  the  interaction).  However,  our
study  is  clearly  underpowered  for  this  analysis,  particularly
in  the  group  with  severe  LV  dysfunction.  Thus,  although  our
results  are  only  partially  in  agreement  with  the  ﬁndings  of
Dondo  et  al.,  both  studies  can  only  be  viewed  as  hypothesis-
generating  and  the  question  should  be  addressed  in  larger
studies,  preferably  randomized  clinical  trials.  The  different
results  in  patients  who  survived  to  discharge  highlight  the
importance  of  early  implementation  of  beta-blockers,  which
appear  to  have  a major  impact  early  in  the  course  of  disease,
independently  of  LV  function.
In  our  population,  more  patients  in  the  beta-blocker
group  underwent  percutaneous  coronary  intervention  (PCI)
than  in  the  group  without  beta-blockers  (68.0%  vs.  80.6%).
This  difference  could  be  explained  by  the  fact  that  STEMI
was  slightly  more  frequent  in  the  beta-blocker  group,
and  coronary  anatomy  in  NSTE-ACS  is  more  often  unsuit-
able  for  PCI.  Also,  aspirin  and  double  antiplatelet  therapy
were  used  much  less  in  patients  not  taking  beta-blockers,
as  were  other  drugs  with  signiﬁcant  impact  on  outcome,
such  as  ACEIs  and  statins.  This  may  be  explained  by  the
fact  that  in-hospital  death  was  signiﬁcantly  more  frequent
and  in  some  cases  occurred  very  soon  after  admission  (in
some  cases  before  PCI);  the  rate  of  major  complications
(mechanical  complications,  stroke/TIA  and  major  bleeding)
is  another  possible  explanation  for  our  ﬁndings,  because
these  complications  might  have  precluded  the  use  of  some
drugs.
Limitations
This  was  an  observational  and  non-randomized  study.
However,  propensity-score  matching  enables  the  resulting
limitations  to  be  mitigated  to  some  extent.  It  was  also  a
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single-center  study,  and  so  its  ﬁndings  may  not  be  applicable
to  other  populations  with  different  baseline  characteristics,
especially  since  our  population  had  a  predominance  of  STEMI
cases,  which  is  not  the  case  in  many  other  centers.  Ours  is
a  tertiary  center  with  cases  referred  from  many  other  hos-
pitals  in  the  region  for  urgent  invasive  treatment  of  ACS.
Thus,  some  caution  is  advised  when  translating  our  ﬁndings
to  other  cohorts.
From  our  registry,  it  was  not  possible  to  perform  detailed
analysis  of  the  type  and  dosage  of  beta-blockers,  compliance
with  treatment  over  time,  or  the  reasons  for  not  prescribing
a  beta-blocker.  Concerning  the  latter,  a  study  in  the  1990s
reported  the  presence  of  contraindications  in  18%  of  MI  sur-
vivors,  the  most  common  of  which  were  bronchial  asthma
or  chronic  obstructive  lung  disease  (7%),  heart  failure  con-
trolled  only  by  >80  mg  of  furosemide  daily  or  digoxin  (7%),
sinus  bradycardia  (4%),  AV  block  (5%)  and  hypotension  (5%).5
In  that  study,  only  51%  of  MI  survivors  were  discharged  on
a  beta-blocker  and  although  82%  had  no  contraindication,
only  58%  of  this  group  received  a  beta-blocker.  Moreover,
most  patients  received  a  signiﬁcantly  lower  dosage  than
those  shown  to  be  effective  in  reducing  mortality.  It is  also
important  to  remember  that  in  the  1990s,  most  available
beta-blockers  were  not  cardioselective.  A  more  recent  study
that  analyzed  the  reasons  recorded  for  not  prescribing  a
beta-blocker  (with  a  rate  of  beta-blocker  prescription  after
MI  in  the  overall  population  of  80%)  showed  that  half  of  the
small  number  of  patients  who  did  not  receive  beta-blockers
had  contraindications.11 The  rate  of  beta-blocker  prescrip-
tion  in  this  study  was  similar  to  ours  and  thus  only  about
10%  of  the  overall  population  would  be  expected  have  con-
traindications,  which  probably  would  not  have  affected  our
results.  Regarding  compliance,  two  recent  papers  showed
that  overall  long-term  compliance  with  beta-blockers  is  high
--  after  one  year,  the  proportion  of  patients  still  on  a  beta-
blocker  had  fallen  by  only  4%,  with  around  80%  of  MI  patients
still  taking  the  drug.23,24 The  same  authors  also  report  that
if  the  medication  is  not  prescribed  at  discharge  it  is  highly
unlikely  to  be  prescribed  later.  For  this  reason,  the  lack  of
information  on  compliance  probably  does  not  signiﬁcantly
affect  our  results.
Conclusions
Our  study,  in  a  contemporary  ACS  population,  conﬁrms  that
the  beneﬁts  of  beta-blocker  use  after  ACS  on  top  of  all
other  guideline-recommended  treatments  are  still  signiﬁ-
cant,  particularly  when  prescribed  early.  This  is  true  not
only  in  patients  with  LV  dysfunction  but  also  in  patients  with
normal  or  mild  to  moderate  LV  dysfunction.
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